Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 22
4 127
3 150
2 51
1 25
NEB 4
Curative setting
A 53
C 2
NEB 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 4
Breast Cancer 35
Endocrine Tumours 21
Gastrointestinal Cancers 69
Genitourinary Cancers 70
Gynaecological Malignancies 38
Head and neck cancer 12
Non-cancerous soft-tissue tumour 1
Sarcoma 11
Skin Cancers 29
TMB-H solid tumours 1
Thoracic Malignancies 82
Tumor agnostic 6
Curative setting
Brain Tumours 2
Breast Cancer 9
Endocrine Tumours 0
Gastrointestinal Cancers 16
Genitourinary Cancers 3
Gynaecological Malignancies 1
Head and neck cancer 1
Non-cancerous soft-tissue tumour 0
Sarcoma 2
Skin Cancers 14
TMB-H solid tumours 0
Thoracic Malignancies 10
Tumor agnostic 0

The ESMO-MCBS Scorecards

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Therapeutic Indication Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Lenvatinib Pembrolizumab Sunitinib Treatment of adults with advanced renal cell carcinoma in combination with pembrolizumab as first-line treatment CLEAR
    Genitourinary Cancers
    		 Renal cell cancer - CLEAR

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Pembrolizumab ChT (paclitaxel + carboplatin) Placebo plus ChT (paclitaxel + carboplatin) In combination with ChT as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early‑stage triple‑negative breast cancer at high risk of recurrence KEYNOTE-522
    Breast Cancer
    		 Early Breast Cancer Triple-negative KEYNOTE-522

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Enfortumab vedotin - Investigator-chosen ChT (standard docetaxel, paclitaxel or vinflunine) Treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor EV-301
    Genitourinary Cancers
    		 Urothelial Carcinoma - EV-301

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Pembrolizumab - Single arm (Phase II) Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy KEYNOTE-057
    Genitourinary Cancers
    		 Urothelial Carcinoma - KEYNOTE-057

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Nivolumab Fluoropyrimidine and platinum ChT (FOLFOX or CAPOX) ChT (FOLFOX or CAPOX) First-line treatment for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and oesophageal adenocarcinoma CheckMate 649
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction cancer and oesophageal adenocarcinoma - CheckMate 649

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Nivolumab Fluoropyrimidine and platinum ChT (FOLFOX or CAPOX) ChT (FOLFOX or CAPOX) First‑line treatment for patients with HER2‑negative advanced or metastatic gastric, gastroesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a CPS ≥5 CheckMate 649
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction cancer and oesophageal adenocarcinoma HER2- PD-L1 CPS ≥5 CheckMate 649

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Pralsetinib - Single arm Treatment for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test ARROW
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer RET fusion-positive ARROW

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Pralsetinib - Single arm Treatment for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor ARROW
    Breast Cancer
    		 Non-small-cell Lung Cancer RET fusion-positive ARROW

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Pembrolizumab - Single arm cohort study Patients with unresectable or metastatic dMMR/MSI-H solid tumours that have progressed following prior treatment and have no alternative treatment options KEYNOTE-158 - Cohort K
    Tumour agnostic
    		 - dMMR/MSI-H KEYNOTE-158 - Cohort K

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Trastuzumab ChT (cisplatin + capecitabine or 5-FU) ChT HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction in patients who have not received prior anti-cancer treatment for their metastatic disease ToGA
    Gastrointestinal Cancers
    		 Stomach or gastroesophageal junction cancer HER2+ ToGA

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Ivosidenib - Placebo For adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy. ClarIDHy
    Gastrointestinal Cancers
    		 Cholangiocarcinoma IDH1 ClarIDHy

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Mobocertinib - Single arm Locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, with progression on or after platinum-based ChT Study 101
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ exon 20 insertion mutations Study 101

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      2
    Tisotumab vedotin - Single arm (Phase II) Adult patients with recurrent or metastatic cervical cancer with disease progression on or after ChT innovaTV 204
    Gynaecological Malignancies
    		 Cervical Cancer - innovaTV 204

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      2
    Trifluridine/Tipiracil (TAS-102) - Placebo Treatment of patients with mCRC in patients who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based ChT, anti-VEGF agents and anti-EGFR agents RECOURSE
    Gastrointestinal Cancers
    		 Colorectal Cancer - RECOURSE

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Pembrolizumab - ChT ((5-fluorouracil–based therapy with or without bevacizumab or cetuximab) First-line treatment of adults with MSI-H or dMMR mCRC KEYNOTE-177
    Gastrointestinal Cancers
    		 Colorectal Cancer dMMR or MSI-H KEYNOTE-177

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Cabozantinib - Placebo Treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy COSMIC-311
    Endocrine Tumours
    		 Thyroid cancer - differentiated - COSMIC-311

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Pralsetinib - Single arm Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant MTC who require systemic therapy ARROW
    Endocrine Tumours
    		 Thyroid Cancer - medullary RET-mutant ARROW

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Pralsetinib - Single arm Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic therapy and who are RAI-refractory ARROW
    Endocrine Tumours
    		 Thyroid cancer - differentiated RET fusion-positive ARROW

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Atezolizumab - Best supportive care Adjuvant treatment following resection and platinum-based ChT for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥1% of tumor cells IMpower010
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer PD-L1 ≥1% IMpower010

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Pembrolizumab ChT with our without bevacizumab Placebo + ChT with our without bevacizumab Persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥1 KEYNOTE-826
    Gynaecological Malignancies
    		 Cervical Cancer PD-L1 (CPS ≥1) KEYNOTE-826

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Pembrolizumab Cisplatin and 5-FU Placebo + cisplatin and 5-FU First-line treatment locally advanced or metastatic oesophageal or gastroesophageal junction carcinoma that is not amenable to surgical resection or definitive CRT in combination with platinum- and fluoropyrimidine-based ChT KEYNOTE-590
    Gastrointestinal Cancers
    		 Oesophageal or gastroesophageal junction carcinoma HER2- GEJ (all randomized) KEYNOTE-590

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Pembrolizumab Platinum and fluoropyrimidine-based chemotherapy Placebo + cisplatin and 5-FU Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus in adults whose tumours express PD-L1 with a CPS ≥ 10 KEYNOTE-590
    Gastrointestinal Cancers
    		 Oesophageal squamous cell carcinoma PD-L1 CPS ≥10 KEYNOTE-590

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Pembrolizumab Cisplatin and 5-FU ChT Placebo + cisplatin and 5-FU ChT First-line treatment KEYNOTE-590
    Gastrointestinal Cancers
    		 Oesophageal squamous cell carcinoma HER2- GEJ (squamous cell) KEYNOTE-590

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Pembrolizumab Cisplatin and 5-FU ChT Placebo + cisplatin and 5-FU ChT First-line treatment KEYNOTE-590
    Gastrointestinal Cancers
    		 Oesophageal squamous cell carcinoma HER2- GEJ PD-L1 (squamous cell) CPS ≥10 KEYNOTE-590

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Nab-sirolimus - Single arm (Phase II) Efficacy in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa) AMPECT
    Sarcoma
    		 Perivascular epithelioid - AMPECT

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Pembrolizumab - Placebo Adjuvant treatment of adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions KEYNOTE-564
    Genitourinary Cancers
    		 Renal cell cancer - KEYNOTE-564

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Belzutifan - Single arm (Phase II) For adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery MK-6482
    Genitourinary Cancers
    		 von Hippel-Lindau disease-associated Renal Cell Carcinoma - MK-6482

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    FOLFOX (folinic acid, fluorouracil, oxaliplatin) - Symptomatic care Second-line treatment of advanced biliary tract cancer ABC-06
    Gastrointestinal Cancers
    		 Biliary tract cancer - ABC-06

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Tebentafusp - Investigator Choice (either dacarbazine, ipilimumab or pembrolizumab) Treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma IMCgp100-202
    Skin Cancers
    		 Uveal melanoma HLA-A*0201positive IMCgp100-202

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Amivantamab - Single arm Advanced NSCLC with activating EGFR exon 20 insertion mutations, after failure of platinum-based therapy CHRYSALIS
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ exon 20 insertion mutations CHRYSALIS

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.